Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NLNK

NewLink Genetics (NLNK) Stock Price, News & Analysis

NewLink Genetics logo

About NewLink Genetics Stock (NASDAQ:NLNK)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.89
$14.10
52-Week Range
N/A
Volume
N/A
Average Volume
547,540 shs
Market Capitalization
$162.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Remove Ads
Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

NLNK Stock News Headlines

Reproduction DNA and Genetics
What Wall Street expects from NewLink Genetics's earnings
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Best DNA Test for 2024
Newlink Technology Inc.
Newlink Technology Inc (9600)
See More Headlines

NLNK Stock Analysis - Frequently Asked Questions

NewLink Genetics Corp (NASDAQ:NLNK) released its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%.

Based on aggregate information from My MarketBeat watchlists, some other companies that NewLink Genetics investors own include Bristol-Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Gilead Sciences (GILD), SunPower (SPWR) and Sarepta Therapeutics (SRPT).

Company Calendar

Last Earnings
11/06/2019
Today
4/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NLNK
Fax
N/A
Employees
55
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-42,990,000.00
Net Margins
-4,592.84%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$940,000.00
Price / Cash Flow
N/A
Book Value
$2.11 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$162.00 million
Optionable
Not Optionable
Beta
1.17
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NLNK) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners